Reta glucagon-like peptide-1 (GLP-1) receptor agonists provide a groundbreaking method to diabetes management. These innovative drugs function by mimicking the inherent actions of GLP-1, a hormone produced by the gut in response to food. By stimulating GLP-1 receptors in the pancreas, these compounds boost insulin production and inhibit glucagon re

The burgeoning landscape of novel treatments for metabolic management has seen the rise of both retatrutide and tirzepatide, both dual mechanism agonists targeting the GLP-1 and GIP receptors. While sharing a comparable therapeutic goal – improving glycemic control and promoting substantial weight decrease – they exhibit intriguing contrasts in